Injecting platelet-rich plasma into degenerated tendon — mechanism, technique, and the evidence trajectory from VISA-A/PRTEE score at baseline through 12-month follow-up
Understanding why PRP is even considered for tendon pain requires understanding what has actually gone wrong in the tissue. Histologic studies of surgically resected chronic tendinopathy specimens consistently show an absence of inflammatory cells — no neutrophils, minimal lymphocytic infiltrate — contradicting the older "tendinitis" model entirely. Instead, the tissue shows a failed, stalled healing response: disorganized collagen fibers, increased mucoid ground substance, fibroblast (tenocyte) hypercellularity, and ingrowth of small-caliber blood vessels accompanied by nerve fibers (neovascularization with neo-innervation), which is thought to be a major source of the pain itself.
Pathoanatomy of chronic tendinopathy:
• Collagen disorganization: normal tendon has densely packed, parallel type I collagen fibers oriented along the line of tensile force; degenerated tendon shows loss of this parallel architecture, with fibers running in disorganized, wavy, non-linear patterns unable to transmit load efficiently • Ground substance accumulation: increased proteoglycan (particularly decorin and versican) and glycosaminoglycan content gives the tissue a mucoid, gelatinous quality on gross and histologic examination • Tenocyte changes: increased cellularity with rounded, chondrocyte-like morphology rather than the normal spindle-shaped fibroblast appearance — a phenotypic shift sometimes termed "tenocyte-to-chondrocyte-like" transformation • Neovascularization: Doppler ultrasound reliably identifies abnormal blood flow within and around the degenerated tendon; accompanying sensory nerve fibers (calcitonin gene-related peptide and substance P positive) are hypothesized to be a direct anatomic substrate for the chronic pain, independent of mechanical loading • Microtears and failed healing: repetitive submaximal loading is thought to produce microscopic collagen damage that outpaces the tendon's intrinsically slow, hypovascular healing capacity, leading to progressive accumulation of unrepaired matrix damage rather than a single macroscopic tear
Why this matters for PRP rationale: Because the tissue is not actively inflamed but rather stuck in a stalled, degenerative state, the therapeutic goal of PRP is fundamentally different from an anti-inflammatory injection (like corticosteroid). PRP aims to reintroduce a controlled proliferative/regenerative signal — the same growth factors (PDGF, TGF-β, VEGF) that drive the early phases of normal wound healing — into tissue that has failed to progress through those phases on its own. This mechanistic distinction is central to understanding both the rationale for PRP and why it is expected to underperform in acute inflammatory tendon conditions where the pathology is different.
Diagnostic criteria and differential: • Lateral epicondylitis: point tenderness 1 cm distal/anterior to the lateral epicondyle, pain with resisted wrist extension, positive Cozen's test • Patellar tendinopathy: point tenderness at inferior pole of patella, pain with resisted knee extension/single-leg decline squat • Achilles mid-portion tendinopathy: fusiform thickening and tenderness 2–6 cm proximal to the calcaneal insertion, pain with hopping/single-leg heel raise • Must exclude: partial/complete tendon rupture, referred radicular pain, systemic inflammatory arthropathy (which can mimic enthesopathy)
Clinical practice guidelines uniformly position PRP as a second- or third-line intervention. Before biologic injection is considered, patients should have completed a structured trial of activity modification and, critically, an eccentric (or heavy slow resistance) loading exercise program — the single intervention with the strongest and most consistent evidence base across all tendinopathy locations. Skipping this step, or offering PRP as a first-line treatment, is inconsistent with essentially every major society guideline.
Structured conservative treatment ladder:
1. Relative rest and activity modification: reducing (not necessarily eliminating) the aggravating load while maintaining general fitness; complete rest is discouraged as tendon requires mechanical loading stimulus to remodel.
2. Eccentric loading exercise programs: • Alfredson protocol (Achilles): heel-drop eccentric exercises, 3 sets of 15 repetitions, twice daily, 7 days/week for 12 weeks, performed through pain • Stanish/Curwin protocol (patellar): eccentric single-leg squats on a decline board • Mechanism: eccentric loading is hypothesized to stimulate collagen cross-linking and remodeling, normalize neovascularization (reducing Doppler signal), and promote tendon hypertrophy and improved load tolerance over 8–12 weeks • Evidence: multiple randomized trials and systematic reviews support eccentric loading with 60–90% good-to-excellent outcomes at 12 weeks for Achilles tendinopathy specifically; results are more variable for patellar and lateral epicondyle tendinopathy
3. Heavy slow resistance (HSR) training: an alternative to pure eccentric protocols, combining concentric and eccentric phases with progressively increased load; comparable outcomes to eccentric-only programs with better patient adherence in some trials (Beyer et al., Am J Sports Med 2015)
4. Adjuncts: NSAIDs for short-term pain control only (no evidence of altering the underlying degenerative histology, and theoretical concern that early post-injury NSAID use may impair the initial healing response); bracing/orthotics (counterforce brace for lateral epicondylitis); extracorporeal shockwave therapy (ESWT) — moderate evidence, particularly for calcific tendinopathy and as a non-invasive alternative before injection therapy.
Why this order matters clinically: • A meaningful fraction of patients improve with eccentric loading alone, meaning premature escalation to injection exposes patients to unnecessary cost, discomfort, and small procedural risk without benefit • PRP trials that do not mandate a structured, supervised eccentric-loading run-in before enrollment are more susceptible to natural history and regression-to-the-mean effects being misattributed to the injection — a frequently cited methodological weakness in PRP tendinopathy literature (Cochrane review, de Vos et al. and subsequent updates) • AAOS and most sports medicine society guidelines explicitly state PRP should not replace, but rather supplement, an adequate trial of exercise-based rehabilitation
The technical execution of the PRP injection is not a passive deposition — the needling technique itself is considered a therapeutic component independent of the biologic content of the syringe. Real-time ultrasound guidance ensures accurate targeting of the hypoechoic degenerative focus (rather than blind injection into adjacent normal tendon or peritendinous tissue), while the "peppering" or "dry needling" fenestration technique mechanically disrupts the disorganized scar-like tissue, theoretically stimulating a localized bleeding response and a fresh healing cascade even before growth factors act.
Procedural steps:
1. Patient positioning and target confirmation: high-frequency linear ultrasound transducer (typically 10–15 MHz) identifies the hypoechoic, structurally abnormal region within the tendon; Doppler mode maps neovascular channels for reference (and sometimes as a specific target for disruption).
2. Local anesthesia: skin and subcutaneous tissue infiltrated with a small volume of local anesthetic; care is taken to avoid injecting anesthetic directly into the tendon substance, as some local anesthetics (particularly bupivacaine) have documented in vitro chondrotoxic and tenotoxic effects that could theoretically blunt the PRP biologic effect.
3. In-plane or out-of-plane needle advancement: the needle tip is visualized in real time advancing to the target lesion under direct ultrasound visualization, minimizing risk to adjacent neurovascular structures (e.g., posterior interosseous nerve near the lateral epicondyle).
4. Peppering/fenestration technique: the needle is passed through the degenerative tissue multiple times (typically 10–20+ passes) in different trajectories without fully withdrawing from the skin, mechanically disrupting the disorganized collagen matrix and creating multiple microchannels — a technique borrowed from percutaneous tenotomy — while small aliquots of PRP are deposited throughout the lesion with each pass rather than as a single bolus at one depth.
5. Total volume: typically 2–4 mL for lateral epicondylitis (smaller tendon volume) up to 4–6 mL for larger tendons (Achilles, patellar), distributed throughout the pathologic region rather than concentrated at a single point.
Post-procedure protocol: • Relative rest 48–72 hours; avoidance of NSAIDs in the immediate post-injection period (theoretical concern that NSAIDs blunt the intended inflammatory/proliferative cascade the injection aims to trigger — though clinical evidence for this specific interaction is limited) • Gradual reintroduction of eccentric loading exercise beginning around week 1–2, progressing per symptom tolerance • Patients are counseled to expect a transient symptom flare in the first 3–7 days as part of the expected biologic response, distinguishing this from a procedural complication • Number of injections: single-injection protocols are most common in trials, though some clinical practices use a series of 2–3 injections spaced 4–6 weeks apart, without strong comparative evidence establishing optimal injection number
In the first six weeks after injection, the tendon undergoes a biologic response that mirrors the early proliferative phase of normal wound healing, deliberately reintroduced into tissue that had stalled in a chronic degenerative state. This phase is characterized by fibroblast recruitment and proliferation, increased collagen synthesis, and — counterintuitively given that pathologic neovascularization is part of the original problem — a transient increase in local vascularity as part of the expected proliferative response, distinct from the abnormal, painful neovascularization of untreated tendinosis.
Sequence of biologic events (extrapolated from animal tendon-healing models and limited human biopsy data):
1. Days 0–3 — Acute response: platelet degranulation releases PDGF, TGF-β, VEGF, and EGF directly into the degenerative focus; local fibrin clot formation from residual plasma fibrinogen creates a provisional scaffold; a mild, self-limited local inflammatory-like response occurs even in the absence of a true inflammatory cell infiltrate, likely mediated by cytokine signaling rather than neutrophil recruitment — this correlates with the commonly reported post-injection pain flare.
2. Days 3–14 — Cellular recruitment and proliferation: PDGF and TGF-β chemotactically recruit fibroblasts/tenocytes and mesenchymal progenitor cells to the injection site; VEGF drives angiogenic sprouting, transiently increasing microvascular density; tenocyte proliferation rate increases substantially above the degenerated tendon's baseline (which is itself often already hypercellular, but with dysfunctional, chondrocyte-like cells rather than actively synthetic fibroblasts).
3. Weeks 2–6 — Matrix synthesis and early remodeling: increased type I and type III procollagen gene expression; total collagen content increases; the type I:type III collagen ratio — which is pathologically decreased in tendinosis (more of the weaker, immature type III collagen) — begins shifting back toward the normal tendon ratio dominated by type I; early fiber realignment begins under the influence of mechanical loading reintroduced through supervised rehabilitation.
4. The neovascularization paradox: pathologic tendinosis already features abnormal neovascularization associated with pain (via accompanying sensory nerve fibers). PRP's growth factor payload (particularly VEGF) further stimulates angiogenesis in the short term as part of the intended proliferative healing response. Longitudinal ultrasound Doppler studies show this vascularity is often transiently increased at 6 weeks before decreasing toward more normal levels by 3–6 months as the tissue matures and remodels — clinicians should not interpret an early increase in Doppler signal as treatment failure.
5. Why timing of rehabilitation matters: mechanical loading is a critical co-signal for productive collagen fiber alignment during this window — animal and clinical data both suggest that combining PRP injection with a structured, progressively loaded eccentric exercise program produces better fiber organization than injection with rest alone, reinforcing that PRP is an adjunct to, not a replacement for, mechanotherapy.
The clinical bottom line on PRP for tendinopathy is more nuanced than either PRP advocates or skeptics often present. Meta-analyses generally do show statistically significant improvement in validated patient-reported outcome measures compared to baseline, and often compared to control injections, at intermediate-to-late follow-up (6–12 months) — with the most consistent, higher-quality evidence for lateral epicondylitis. However, effect sizes are frequently below the threshold considered a minimal clinically important difference, and many individual trials are small, heterogeneous in PRP formulation, and at risk of bias, leading major guideline bodies to grade the overall evidence as low-to-moderate quality.
Validated outcome measures used in tendinopathy trials: • VISA-A (Victorian Institute of Sport Assessment–Achilles): 8-item, 0–100 scale assessing pain, function, and activity level; higher score = better outcome; a 100-point score represents an asymptomatic, fully functional tendon. • VISA-P: analogous instrument for patellar tendinopathy. • PRTEE (Patient-Rated Tennis Elbow Evaluation): 15-item, 0–100 scale assessing pain and functional disability from lateral epicondylitis; lower score = better outcome. • Minimal clinically important difference (MCID): generally cited around 10–13 points for these instruments — many positive PRP trials report improvements in this range or somewhat above it, meaning statistical significance and clinical meaningfulness do not always align comfortably.
Landmark and influential trials:
• Mishra et al. (Am J Sports Med, 2014): multicenter RCT, leukocyte-rich PRP vs. active control (bupivacaine) injection for chronic lateral epicondylitis; PRP group showed significantly greater improvement in pain (VAS) and PRTEE-equivalent function scores at 12 weeks and 12 months (though the 12-week primary endpoint result was more consistently significant than earlier interim analyses) — one of the more influential trials supporting PRP for tennis elbow specifically.
• de Vos et al. (JAMA, 2010) and follow-up: RCT of PRP vs. saline injection for chronic Achilles tendinopathy; found NO significant difference in VISA-A score improvement between PRP and saline at any time point up to 1 year — a frequently cited negative trial that tempered early enthusiasm for PRP in Achilles tendinopathy specifically.
• Krogh et al. (Am J Sports Med, 2013): RCT for lateral epicondylitis comparing PRP, saline, and corticosteroid; found no significant difference between PRP and saline at 3 months, though corticosteroid showed early but non-durable benefit — reinforcing that needling/placebo effects account for a meaningful fraction of the response seen in some PRP trials.
• Cochrane systematic review (updates through the 2010s–2020s) and multiple orthopedic-society meta-analyses: conclude that PRP shows a small-to-moderate benefit over control for lateral epicondylitis at 6–12 months, but evidence for patellar tendinopathy and Achilles tendinopathy is weaker and more inconsistent, and overall evidence quality across sites is frequently graded low to moderate due to trial heterogeneity (different PRP preparation systems, leukocyte content, injection volume, needling technique, and control comparator).
Interpreting the discrepancy across trials: • Leukocyte content: LR-PRP has shown somewhat more consistent benefit in tendon (vs. LP-PRP, which shows more benefit in intra-articular joint applications) in subgroup analyses, though this is not universally replicated • Comparator matters enormously: trials comparing PRP to saline show larger effect sizes than trials comparing PRP to another active injection (corticosteroid, autologous blood, dry needling alone) — some of the apparent PRP effect may be attributable to the needling/fenestration procedure itself rather than the biologic content • Natural history and regression to the mean: chronic tendinopathy has a fluctuating course, and trials without an adequate no-treatment or long-term observation arm may overestimate the specific treatment effect of PRP • Publication and sponsorship bias: as with many orthobiologic interventions, industry-sponsored or single-center trials tend to report more favorable results than large, independent, multicenter trials
The most defensible summary consistent with AAOS Clinical Practice Guidelines and Cochrane-level reviews: PRP for lateral epicondylitis has the best-supported, though still only moderate-quality, evidence for meaningful improvement at 6–12 months, particularly in patients who have failed a structured eccentric-exercise program. Evidence for patellar and Achilles tendinopathy remains weaker and inconsistent across trials. PRP should be presented to patients as an adjunctive option with a reasonable mechanistic rationale and modest supporting evidence — not as a proven cure — and always in the context of continued, structured rehabilitation.